MBRace Therapeutics Stock

www.mbracetrx.com/Healthcare / BioTech & PharmaFounded: 2020

MBrace Therapeutics is dedicated to transforming cancer treatment through innovative discovery, aiming to translate research into transformative therapies for cancer patients. The team comprises experienced experts across cancer drug development, working together to offer new and improved treatment options. MBrace's approach integrates the expertise of researchers, the needs of patients, the guidance of physicians, and the team's dedication, fostering advancements in cancer therapeutics. Each team member's personal experience with cancer underpins their commitment to patient care, driving the development of novel treatment options.

Register To Buy and Sell Shares

For more details on financing and valuation for MBRace Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access MBRace Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like MBRace Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Yongjian Wu Ph.D
Chief Development Officer & Head of CMC
Renata Pasqualini Ph.D
Co-Founder, Chief Scientific Officer & Scientific Advisor
Isan Chen MD
Co-Founder, Chief Executive Officer & President
Wadih Arap Ph.D
Co-Founder & Scientific Advisor

Board Members

Carolyn Ng Ph.D
Eric Pham Ph.D
Cowen Healthcare Investments
Mariana Mihalusova
Monal Mehta Ph.D
Avidity Partners
Racquel Bracken
Robert More
Alta Partners

Frequently Asked Questions About MBRace Therapeutics’ Stock

Can you buy MBRace Therapeutics’ stock?
MBRace Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy MBRace Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell MBRace Therapeutics’ stock?
Yes, you can sell stock of a private company like MBRace Therapeutics. Forge can help you sell your MBRace Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is MBRace Therapeutics’ stock price?
MBRace Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access MBRace Therapeutics’ private market stock price with Forge Data.
What is MBRace Therapeutics’ stock ticker symbol?
MBRace Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

MBrace Therapeutics Raises $85M in Series B Financing
MBrace Therapeutics, a San Diego, CA-based biopharmaceutical company, raised $85M in Series B funding. The round, which brought the total amount to $110M, was led by TPG, investing through its dedicated life sciences fund, TPG Life Sciences Innovations (TPG LSI), and its multi-sector impact strategy, The Rise Fund. The round also included new investors Avidity Partners and Cowen Healthcare Investments, as well as existing Series A investors, Venrock and Alta Partners.
Updated on: Jun 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.